Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 94 entries
Sorted by: Best Match Show Resources per page
Correlation between Chemical Composition of Curcuma domestica and Curcuma xanthorrhiza and Their Antioxidant Effect on Human Low-Density Lipoprotein Oxidation.

Evidence-based complementary and alternative medicine : eCAM

Jantan I, Saputri FC, Qaisar MN, Buang F.
PMID: 23243446
Evid Based Complement Alternat Med. 2012;2012:438356. doi: 10.1155/2012/438356. Epub 2012 Nov 26.

The antioxidant activity of the curcuminoids of Curcuma domestica L. and C. xanthorrhiza Roxb. and eight compounds which are prevalent constituents of their rhizome oils were investigated in an effort to correlate human low-density lipoprotein (LDL) antioxidant activity with...

Cite
Jantan I, Saputri FC, Qaisar MN, et al. Correlation between Chemical Composition of Curcuma domestica and Curcuma xanthorrhiza and Their Antioxidant Effect on Human Low-Density Lipoprotein Oxidation. Evid Based Complement Alternat Med. 2012;2012:438356doi: 10.1155/2012/438356.
Jantan, I., Saputri, F. C., Qaisar, M. N., & Buang, F. (2012). Correlation between Chemical Composition of Curcuma domestica and Curcuma xanthorrhiza and Their Antioxidant Effect on Human Low-Density Lipoprotein Oxidation. Evidence-based complementary and alternative medicine : eCAM, 2012438356. https://doi.org/10.1155/2012/438356
Jantan, Ibrahim, et al. "Correlation between Chemical Composition of Curcuma domestica and Curcuma xanthorrhiza and Their Antioxidant Effect on Human Low-Density Lipoprotein Oxidation." Evidence-based complementary and alternative medicine : eCAM vol. 2012 (2012): 438356. doi: https://doi.org/10.1155/2012/438356
Jantan I, Saputri FC, Qaisar MN, Buang F. Correlation between Chemical Composition of Curcuma domestica and Curcuma xanthorrhiza and Their Antioxidant Effect on Human Low-Density Lipoprotein Oxidation. Evid Based Complement Alternat Med. 2012;2012:438356. doi: 10.1155/2012/438356. Epub 2012 Nov 26. PMID: 23243446; PMCID: PMC3519093.
Copy Download .nbib Format: NLM
Lipolysis stimulating peptides of potato protein hydrolysate effectively suppresses high-fat-diet-induced hepatocyte apoptosis and fibrosis in aging rats.

Food & nutrition research

Chiang WD, Huang CY, Paul CR, Lee ZY, Lin WT.
PMID: 27415158
Food Nutr Res. 2016 Jul 12;60:31417. doi: 10.3402/fnr.v60.31417. eCollection 2016.

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is one of the most common outcomes of obesity and is characterized by the accumulation of triglycerides, increased tissue apoptosis, and fibrosis. NAFLD is more common among elderly than in younger age groups,...

Cite
Chiang WD, Huang CY, Paul CR, et al. Lipolysis stimulating peptides of potato protein hydrolysate effectively suppresses high-fat-diet-induced hepatocyte apoptosis and fibrosis in aging rats. Food Nutr Res. 2016;60:31417doi: 10.3402/fnr.v60.31417.
Chiang, W. D., Huang, C. Y., Paul, C. R., Lee, Z. Y., & Lin, W. T. (2016). Lipolysis stimulating peptides of potato protein hydrolysate effectively suppresses high-fat-diet-induced hepatocyte apoptosis and fibrosis in aging rats. Food & nutrition research, 6031417. https://doi.org/10.3402/fnr.v60.31417
Chiang, Wen-Dee, et al. "Lipolysis stimulating peptides of potato protein hydrolysate effectively suppresses high-fat-diet-induced hepatocyte apoptosis and fibrosis in aging rats." Food & nutrition research vol. 60 (2016): 31417. doi: https://doi.org/10.3402/fnr.v60.31417
Chiang WD, Huang CY, Paul CR, Lee ZY, Lin WT. Lipolysis stimulating peptides of potato protein hydrolysate effectively suppresses high-fat-diet-induced hepatocyte apoptosis and fibrosis in aging rats. Food Nutr Res. 2016 Jul 12;60:31417. doi: 10.3402/fnr.v60.31417. eCollection 2016. PMID: 27415158; PMCID: PMC4944597.
Copy Download .nbib Format: NLM
Low density lipoproteins and atherosclerosis-quantity or quality?.

Redox report : communications in free radical research

Raal FJ, Areias AJ, Joffe BI.
PMID: 27414271
Redox Rep. 1995 May;1(3):171-6. doi: 10.1080/13510002.1995.11746980.

Oxidative modification of low density lipoprotein (LDL) appears to be important in the pathogenesis of atherosclerosis. Inhibiting the oxidation of LDL may retard or prevent the atherogenic process. However, susceptibility of LDL to oxidation in vitro and its atherogenicity...

Cite
Raal FJ, Areias AJ, Joffe BI. Low density lipoproteins and atherosclerosis-quantity or quality?. Redox Rep. 1995;1(3):171-6doi: 10.1080/13510002.1995.11746980.
Raal, F. J., Areias, A. J., & Joffe, B. I. (1995). Low density lipoproteins and atherosclerosis-quantity or quality?. Redox report : communications in free radical research, 1(3), 171-6. https://doi.org/10.1080/13510002.1995.11746980
Raal, F J, et al. "Low density lipoproteins and atherosclerosis-quantity or quality?." Redox report : communications in free radical research vol. 1,3 (1995): 171-6. doi: https://doi.org/10.1080/13510002.1995.11746980
Raal FJ, Areias AJ, Joffe BI. Low density lipoproteins and atherosclerosis-quantity or quality?. Redox Rep. 1995 May;1(3):171-6. doi: 10.1080/13510002.1995.11746980. PMID: 27414271.
Copy Download .nbib Format: NLM
Anti-restenosis Trials.

Current interventional cardiology reports

de Feyter PJ, Vos J, Rensing BJ.
PMID: 11096683
Curr Interv Cardiol Rep. 2000 Nov;2(4):326-331.

The high frequency of restenosis after percutaneous coronary angioplasty is still a major clinical problem. It occurs in 30% to 60% of patients and limits the long-term success of angioplasty. Many clinical trials have been conducted to resolve this...

Cite
de Feyter PJ, Vos J, Rensing BJ. Anti-restenosis Trials. Curr Interv Cardiol Rep. 2000;2(4):326-331
de Feyter PJ, Vos, J., & Rensing, B. J. (2000). Anti-restenosis Trials. Current interventional cardiology reports, 2(4), 326-331.
de Feyter PJ, et al. "Anti-restenosis Trials." Current interventional cardiology reports vol. 2,4 (2000): 326-331.
de Feyter PJ, Vos J, Rensing BJ. Anti-restenosis Trials. Curr Interv Cardiol Rep. 2000 Nov;2(4):326-331. PMID: 11096683.
Copy Download .nbib Format: NLM
Dopamine induces cell death, lipid peroxidation and DNA base damage in a catecholaminergic cell line derived from the central nervous system.

Neurotoxicity research

Masserano JM, Baker I, Venable D, Gong L, Zullo SJ, Merril CR, Wyatt RJ.
PMID: 12835100
Neurotox Res. 2000 Feb;1(3):171-9. doi: 10.1007/BF03033288.

Dopamine can be autoxidized to superoxides and quinones. Superoxides can form hydroxyl radicals that are highly reactive with lipids, proteins and DNA leading to neuronal damage and cell death. We used a clonal catecholaminergic cell line (CATH.a) derived from...

Cite
Masserano JM, Baker I, Venable D, et al. Dopamine induces cell death, lipid peroxidation and DNA base damage in a catecholaminergic cell line derived from the central nervous system. Neurotox Res. 2000;1(3):171-9doi: 10.1007/BF03033288.
Masserano, J. M., Baker, I., Venable, D., Gong, L., Zullo, S. J., Merril, C. R., & Wyatt, R. J. (2000). Dopamine induces cell death, lipid peroxidation and DNA base damage in a catecholaminergic cell line derived from the central nervous system. Neurotoxicity research, 1(3), 171-9. https://doi.org/10.1007/BF03033288
Masserano, J M, et al. "Dopamine induces cell death, lipid peroxidation and DNA base damage in a catecholaminergic cell line derived from the central nervous system." Neurotoxicity research vol. 1,3 (2000): 171-9. doi: https://doi.org/10.1007/BF03033288
Masserano JM, Baker I, Venable D, Gong L, Zullo SJ, Merril CR, Wyatt RJ. Dopamine induces cell death, lipid peroxidation and DNA base damage in a catecholaminergic cell line derived from the central nervous system. Neurotox Res. 2000 Feb;1(3):171-9. doi: 10.1007/BF03033288. PMID: 12835100.
Copy Download .nbib Format: NLM
Sustained Intramural Retention and Regional Redistribution Following Local Vascular Delivery of Polylactic-Coglycolic Acid and Liposomal Nanoparticulate Formulations Containing Probucol.

Journal of cardiovascular pharmacology and therapeutics

Klugherz BD, Meneveau N, Chen W, Wade-Whittaker F, Papandreou G, Levy R, Wilensky RL.
PMID: 10684538
J Cardiovasc Pharmacol Ther. 1999 Jul;4(3):167-174. doi: 10.1177/107424849900400306.

BACKGROUND: Probucol reduces restenosis after angioplasty, provided oral administration is begun 1 month before the procedure. Local vascular delivery of a nonoparticulate formulation of probucol may obviate the need for drug loading by acutely raising arterial intramural concentration while...

Cite
Klugherz BD, Meneveau N, Chen W, et al. Sustained Intramural Retention and Regional Redistribution Following Local Vascular Delivery of Polylactic-Coglycolic Acid and Liposomal Nanoparticulate Formulations Containing Probucol. J Cardiovasc Pharmacol Ther. 1999;4(3):167-174doi: 10.1177/107424849900400306.
Klugherz, B. D., Meneveau, N., Chen, W., Wade-Whittaker, F., Papandreou, G., Levy, R., & Wilensky, R. L. (1999). Sustained Intramural Retention and Regional Redistribution Following Local Vascular Delivery of Polylactic-Coglycolic Acid and Liposomal Nanoparticulate Formulations Containing Probucol. Journal of cardiovascular pharmacology and therapeutics, 4(3), 167-174. https://doi.org/10.1177/107424849900400306
Klugherz, et al. "Sustained Intramural Retention and Regional Redistribution Following Local Vascular Delivery of Polylactic-Coglycolic Acid and Liposomal Nanoparticulate Formulations Containing Probucol." Journal of cardiovascular pharmacology and therapeutics vol. 4,3 (1999): 167-174. doi: https://doi.org/10.1177/107424849900400306
Klugherz BD, Meneveau N, Chen W, Wade-Whittaker F, Papandreou G, Levy R, Wilensky RL. Sustained Intramural Retention and Regional Redistribution Following Local Vascular Delivery of Polylactic-Coglycolic Acid and Liposomal Nanoparticulate Formulations Containing Probucol. J Cardiovasc Pharmacol Ther. 1999 Jul;4(3):167-174. doi: 10.1177/107424849900400306. PMID: 10684538.
Copy Download .nbib Format: NLM
Structure-activity relationship of antioxidants for inhibitors of linoleic acid hydroperoxide-induced toxicity in cultured human umbilical vein endothelial cells.

Cytotechnology

Kaneko T, Baba N, Matsuo M.
PMID: 19003280
Cytotechnology. 2001 Jan;35(1):43-55. doi: 10.1023/A:1008139412588.

Structure-activity relationship of antioxidants for the protective effects on linoleic acid hydroperoxide (LOOH)-induced toxicity were examined in cultured human umbilical vein endothelial cells. alpha-Tocopherol, 2,2,5,7,8-pentamethylchroman-6-ol, butylated hydroxytoluene, probucol, and fatty acid esters of ascorbic acid provided efficient protection against...

Cite
Kaneko T, Baba N, Matsuo M. Structure-activity relationship of antioxidants for inhibitors of linoleic acid hydroperoxide-induced toxicity in cultured human umbilical vein endothelial cells. Cytotechnology. 2001;35(1):43-55doi: 10.1023/A:1008139412588.
Kaneko, T., Baba, N., & Matsuo, M. (2001). Structure-activity relationship of antioxidants for inhibitors of linoleic acid hydroperoxide-induced toxicity in cultured human umbilical vein endothelial cells. Cytotechnology, 35(1), 43-55. https://doi.org/10.1023/A:1008139412588
Kaneko, T, et al. "Structure-activity relationship of antioxidants for inhibitors of linoleic acid hydroperoxide-induced toxicity in cultured human umbilical vein endothelial cells." Cytotechnology vol. 35,1 (2001): 43-55. doi: https://doi.org/10.1023/A:1008139412588
Kaneko T, Baba N, Matsuo M. Structure-activity relationship of antioxidants for inhibitors of linoleic acid hydroperoxide-induced toxicity in cultured human umbilical vein endothelial cells. Cytotechnology. 2001 Jan;35(1):43-55. doi: 10.1023/A:1008139412588. PMID: 19003280; PMCID: PMC3466616.
Copy Download .nbib Format: NLM
Synergistic efficacy of concurrent treatment with cilostazol and probucol on the suppression of reactive oxygen species and inflammatory markers in cultured human coronary artery endothelial cells.

The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology

Park SY, Lee JH, Shin HK, Kim CD, Lee WS, Rhim BY, Shin YW, Hong KW.
PMID: 19967051
Korean J Physiol Pharmacol. 2008 Aug;12(4):165-70. doi: 10.4196/kjpp.2008.12.4.165. Epub 2008 Aug 31.

In the present study, we aimed to identify the synergistic effects of concurrent treatment of low concentrations of cilostazol and probucol to inhibit the oxidative stress with suppression of inflammatory markers in the cultured human coronary artery endothelial cells...

Cite
Park SY, Lee JH, Shin HK, et al. Synergistic efficacy of concurrent treatment with cilostazol and probucol on the suppression of reactive oxygen species and inflammatory markers in cultured human coronary artery endothelial cells. Korean J Physiol Pharmacol. 2008;12(4):165-70doi: 10.4196/kjpp.2008.12.4.165.
Park, S. Y., Lee, J. H., Shin, H. K., Kim, C. D., Lee, W. S., Rhim, B. Y., Shin, Y. W., & Hong, K. W. (2008). Synergistic efficacy of concurrent treatment with cilostazol and probucol on the suppression of reactive oxygen species and inflammatory markers in cultured human coronary artery endothelial cells. The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology, 12(4), 165-70. https://doi.org/10.4196/kjpp.2008.12.4.165
Park, So Youn, et al. "Synergistic efficacy of concurrent treatment with cilostazol and probucol on the suppression of reactive oxygen species and inflammatory markers in cultured human coronary artery endothelial cells." The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology vol. 12,4 (2008): 165-70. doi: https://doi.org/10.4196/kjpp.2008.12.4.165
Park SY, Lee JH, Shin HK, Kim CD, Lee WS, Rhim BY, Shin YW, Hong KW. Synergistic efficacy of concurrent treatment with cilostazol and probucol on the suppression of reactive oxygen species and inflammatory markers in cultured human coronary artery endothelial cells. Korean J Physiol Pharmacol. 2008 Aug;12(4):165-70. doi: 10.4196/kjpp.2008.12.4.165. Epub 2008 Aug 31. PMID: 19967051; PMCID: PMC2788631.
Copy Download .nbib Format: NLM
A second-generation micro/nano capsules of an endogenous primary un-metabolised bile acid, stabilized by Eudragit-alginate complex with antioxidant compounds.

Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society

Mooranian A, Zamani N, Mikov M, Goločorbin-Kon S, Stojanovic G, Arfuso F, Kovacevic B, Al-Salami H.
PMID: 32042255
Saudi Pharm J. 2020 Feb;28(2):165-171. doi: 10.1016/j.jsps.2019.11.017. Epub 2019 Dec 07.

Bile acids (BAs) are amphiphilic compounds and of recently have demonstrated wide range of formulation stabilizing effects. A recent study showed that primary un-metabolised bile acids (PUBAs) have β-cell protective effects, and synergistic antidiabetic effects when combined with antioxidant...

Cite
Mooranian A, Zamani N, Mikov M, et al. A second-generation micro/nano capsules of an endogenous primary un-metabolised bile acid, stabilized by Eudragit-alginate complex with antioxidant compounds. Saudi Pharm J. 2019;28(2):165-171doi: 10.1016/j.jsps.2019.11.017.
Mooranian, A., Zamani, N., Mikov, M., Goločorbin-Kon, S., Stojanovic, G., Arfuso, F., Kovacevic, B., & Al-Salami, H. (2020). A second-generation micro/nano capsules of an endogenous primary un-metabolised bile acid, stabilized by Eudragit-alginate complex with antioxidant compounds. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 28(2), 165-171. https://doi.org/10.1016/j.jsps.2019.11.017
Mooranian, Armin, et al. "A second-generation micro/nano capsules of an endogenous primary un-metabolised bile acid, stabilized by Eudragit-alginate complex with antioxidant compounds." Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society vol. 28,2 (2020): 165-171. doi: https://doi.org/10.1016/j.jsps.2019.11.017
Mooranian A, Zamani N, Mikov M, Goločorbin-Kon S, Stojanovic G, Arfuso F, Kovacevic B, Al-Salami H. A second-generation micro/nano capsules of an endogenous primary un-metabolised bile acid, stabilized by Eudragit-alginate complex with antioxidant compounds. Saudi Pharm J. 2020 Feb;28(2):165-171. doi: 10.1016/j.jsps.2019.11.017. Epub 2019 Dec 07. PMID: 32042255; PMCID: PMC7000308.
Copy Download .nbib Format: NLM
Automated PET-RAFT Polymerization Towards Pharmaceutical Amorphous Solid Dispersion Development.

ACS applied polymer materials

Upadhya R, Punia A, Kanagala MJ, Liu L, Lamm M, Rhodes TA, Gormley AJ.
PMID: 34368765
ACS Appl Polym Mater. 2021 Mar 12;3(3):1525-1536. doi: 10.1021/acsapm.0c01376. Epub 2021 Feb 15.

In pharmaceutical oral drug delivery development, about 90% of drugs in the pipeline have poor aqueous solubility leading to severe challenges with oral bioavailability and translation to effective and safe drug products. Amorphous solid dispersions (ASDs) have been utilized...

Cite
Upadhya R, Punia A, Kanagala MJ, et al. Automated PET-RAFT Polymerization Towards Pharmaceutical Amorphous Solid Dispersion Development. ACS Appl Polym Mater. 2021;3(3):1525-1536doi: 10.1021/acsapm.0c01376.
Upadhya, R., Punia, A., Kanagala, M. J., Liu, L., Lamm, M., Rhodes, T. A., & Gormley, A. J. (2021). Automated PET-RAFT Polymerization Towards Pharmaceutical Amorphous Solid Dispersion Development. ACS applied polymer materials, 3(3), 1525-1536. https://doi.org/10.1021/acsapm.0c01376
Upadhya, Rahul, et al. "Automated PET-RAFT Polymerization Towards Pharmaceutical Amorphous Solid Dispersion Development." ACS applied polymer materials vol. 3,3 (2021): 1525-1536. doi: https://doi.org/10.1021/acsapm.0c01376
Upadhya R, Punia A, Kanagala MJ, Liu L, Lamm M, Rhodes TA, Gormley AJ. Automated PET-RAFT Polymerization Towards Pharmaceutical Amorphous Solid Dispersion Development. ACS Appl Polym Mater. 2021 Mar 12;3(3):1525-1536. doi: 10.1021/acsapm.0c01376. Epub 2021 Feb 15. PMID: 34368765; PMCID: PMC8336633.
Copy Download .nbib Format: NLM
Serum metabolomics of end-stage renal disease patients with depression: potential biomarkers for diagnosis.

Renal failure

Yuan D, Kuan T, Ling H, Wang H, Feng L, Zhao Q, Li J, Ran J.
PMID: 34723750
Ren Fail. 2021 Dec;43(1):1479-1491. doi: 10.1080/0886022X.2021.1994995.

BACKGROUND: End-stage renal disease (ESRD) is the final stage during the development of renal failure. Depression is the most common psychiatric disorder in patients with ESRD, which in turn aggravates the progression of renal failure, however, its underlying mechanism...

Cite
Yuan D, Kuan T, Ling H, et al. Serum metabolomics of end-stage renal disease patients with depression: potential biomarkers for diagnosis. Ren Fail. 2021;43(1):1479-1491doi: 10.1080/0886022X.2021.1994995.
Yuan, D., Kuan, T., Ling, H., Wang, H., Feng, L., Zhao, Q., Li, J., & Ran, J. (2021). Serum metabolomics of end-stage renal disease patients with depression: potential biomarkers for diagnosis. Renal failure, 43(1), 1479-1491. https://doi.org/10.1080/0886022X.2021.1994995
Yuan, Dezhi, et al. "Serum metabolomics of end-stage renal disease patients with depression: potential biomarkers for diagnosis." Renal failure vol. 43,1 (2021): 1479-1491. doi: https://doi.org/10.1080/0886022X.2021.1994995
Yuan D, Kuan T, Ling H, Wang H, Feng L, Zhao Q, Li J, Ran J. Serum metabolomics of end-stage renal disease patients with depression: potential biomarkers for diagnosis. Ren Fail. 2021 Dec;43(1):1479-1491. doi: 10.1080/0886022X.2021.1994995. PMID: 34723750; PMCID: PMC8567927.
Copy Download .nbib Format: NLM
Chemotherapy-induced hearing loss: the applications of bio-nanotechnologies and bile acid-based delivery matrices.

Therapeutic delivery

Foster T, Ionescu C, Walker D, Jones M, Wagle S, Kovacevic B, Brown D, Mikov M, Mooranian A, Al-Salami H.
PMID: 34697955
Ther Deliv. 2021 Oct;12(10):723-737. doi: 10.4155/tde-2021-0050. Epub 2021 Oct 26.

Advancement in the prevention of chemotherapy-induced hearing loss has proposed new nano-based delivery matrices that can target inner ear regions most damaged by chemotherapy. Chemotherapy agents (e.g., cisplatin) induce increased reactive oxygen species formation in the inner ear that...

Cite
Foster T, Ionescu C, Walker D, et al. Chemotherapy-induced hearing loss: the applications of bio-nanotechnologies and bile acid-based delivery matrices. Ther Deliv. 2021;12(10):723-737doi: 10.4155/tde-2021-0050.
Foster, T., Ionescu, C., Walker, D., Jones, M., Wagle, S., Kovacevic, B., Brown, D., Mikov, M., Mooranian, A., & Al-Salami, H. (2021). Chemotherapy-induced hearing loss: the applications of bio-nanotechnologies and bile acid-based delivery matrices. Therapeutic delivery, 12(10), 723-737. https://doi.org/10.4155/tde-2021-0050
Foster, Thomas, et al. "Chemotherapy-induced hearing loss: the applications of bio-nanotechnologies and bile acid-based delivery matrices." Therapeutic delivery vol. 12,10 (2021): 723-737. doi: https://doi.org/10.4155/tde-2021-0050
Foster T, Ionescu C, Walker D, Jones M, Wagle S, Kovacevic B, Brown D, Mikov M, Mooranian A, Al-Salami H. Chemotherapy-induced hearing loss: the applications of bio-nanotechnologies and bile acid-based delivery matrices. Ther Deliv. 2021 Oct;12(10):723-737. doi: 10.4155/tde-2021-0050. Epub 2021 Oct 26. PMID: 34697955.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 94 entries